(Cervical Cancer) Is Sintilimab Plus Anlotinib Effective? Phase 2 Trial Results
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- February 22, 2022
- 2 min read
On February 22, 2022, Qin Xu and colleagues from Fujian Medical University Cancer Hospital published results in the Journal of Clinical Oncology from a Phase 2 clinical trial evaluating the efficacy and safety of sintilimab (anti-PD-1 antibody) plus anlotinib (tyrosine kinase inhibitor) in previously treated, PD-L1-positive, recurrent/metastatic cervical cancer patients.
Trial Design:
This Phase 2 trial administered sintilimab (200 mg on Day 1) plus anlotinib (10 mg once daily, Days 1–14) on a 3-week cycle to previously treated, PD-L1-positive, recurrent/metastatic cervical cancer patients. The primary endpoint was objective response rate (ORR); secondary endpoints were PFS, OS, and disease control rate (DCR).
Results (N=42 enrolled; N=39 evaluable):
- Primary endpoint ORR: 59.0%
- Disease control rate (DCR): 94.9%
- Median PFS: 9.4 months
- Median OS: Not reached
Safety:
Overall adverse event rate: 85.8%. Most common adverse events: hypothyroidism 33.3%, AST elevation 21.4%, hypertension 19.0%.
Conclusion: Based on the Phase 2 trial results, Qin Xu and colleagues concluded that sintilimab plus anlotinib demonstrated favorable anti-tumor activity with an acceptable tolerability profile in previously treated, PD-L1-positive, recurrent/metastatic cervical cancer patients.
Source: https://ascopubs.org/doi/full/10.1200/JCO.21.02091
Cervical Cancer | Immunotherapy | Sintilimab | Anlotinib
-
Clinical Trial Medications
-
Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4